BTIG Reiterates Buy on BrightSpring Health, Maintains $55 Price Target

BTIG analyst David Larsen has reiterated a Buy rating on BrightSpring Health (NASDAQ: BTSG) and has maintained a price target of $55 for the stock. This endorsement reflects confidence in the company's performance and potential for growth.